SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare gains on inking pact with United Nations-backed Medicines Patent Pool

26 Jun 2013 Evaluate

Shilpa Medicare is currently trading at Rs 262.95, up by 8.85 points or 3.48% from its previous closing of Rs 254.10 on the BSE.

The scrip opened at Rs 264.65 and has touched a high and low of Rs 280.00 and Rs 260.00 respectively. So far 92123 shares were traded on the counter.

The BSE group 'B' stock of face value Rs 2 has touched a 52 week high of Rs 328.25 on 19-Nov-2012 and a 52 week low of Rs 217.75 on 19-Jun-2013.

Last one week high and low of the scrip stood at Rs 290.00 and Rs 217.75 respectively. The current market cap of the company is Rs 645.23 crore.

The promoters holding in the company stood at 55.88%, while Institutions and Non-Institutions held 10.01% and 34.11% respectively.

Shilpa Medicare and Gilead Sciences have inked pact with United Nations-backed Medicines Patent Pool by entering into agreement to increase the access to medicines for HIV/AIDS treatment. With this initiative, the company will be able to produce five key HIV medicines for sale in over 100 countries depending on the medicine.

As per the agreement, the Karnataka-based firm can produce tenofovir, emtricitabine, cobicistat, elvitegravir and a combination of the four known as -the Quad. For this it will pay 3-5% royalty to the patent-holder Gilead, depending on the medicine.

Shilpa Medicare Share Price

574.45 -16.10 (-2.73%)
24-Jun-2026 10:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1875.60
Dr. Reddys Labs. 1331.95
Cipla 1437.15
Zydus Lifesciences 1110.50
Lupin 2382.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: